Difficulty: Medium
Average Score: 68%
Practice
Currently used dopamine agonists decreasing pituitary prolactin secretion are following:
Correct answer
D
Rationale
In the context of safety pharmacology across the lifespan, understanding the effects of dopamine agonists on pituitary prolactin secretion is crucial. The correct answer is option D, which includes Bromocriptine, Cabergoline, and Pergolide. These dopamine agonists are known to decrease pituitary prolactin secretion through their action on dopamine receptors in the brain.
Bromocriptine is a commonly used dopamine agonist that acts on D2 receptors in the pituitary gland, leading to a decrease in prolactin secretion. Cabergoline and Pergolide also work through similar mechanisms to inhibit prolactin release from the pituitary gland.
Options A, B, and C are incorrect because they do not cover the full range of dopamine agonists that decrease pituitary prolactin secretion. Selecting any one of these options would provide an incomplete answer and could lead to misconceptions about the pharmacological management of prolactin-related disorders.
In an educational context, understanding the specific actions of dopamine agonists on prolactin secretion is essential for healthcare professionals involved in the management of conditions such as hyperprolactinemia, prolactinomas, and related disorders. This knowledge allows for safe and effective prescribing practices across the lifespan, taking into account the unique physiological and pharmacological considerations at different stages of life.
Bromocriptine is a commonly used dopamine agonist that acts on D2 receptors in the pituitary gland, leading to a decrease in prolactin secretion. Cabergoline and Pergolide also work through similar mechanisms to inhibit prolactin release from the pituitary gland.
Options A, B, and C are incorrect because they do not cover the full range of dopamine agonists that decrease pituitary prolactin secretion. Selecting any one of these options would provide an incomplete answer and could lead to misconceptions about the pharmacological management of prolactin-related disorders.
In an educational context, understanding the specific actions of dopamine agonists on prolactin secretion is essential for healthcare professionals involved in the management of conditions such as hyperprolactinemia, prolactinomas, and related disorders. This knowledge allows for safe and effective prescribing practices across the lifespan, taking into account the unique physiological and pharmacological considerations at different stages of life.